Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
PLoS One. 2021 Mar 11;16(3):e0248534. doi: 10.1371/journal.pone.0248534. eCollection 2021.
Minimally invasive surgery (MIS) provides a new approach for patients with hilar cholangiocarcinoma (HCCA). However, whether it can achieve similar outcomes to traditional open surgery (OS) remains controversial.
To assess the safety and feasibility of MIS for HCCA, a systematic review and meta-analysis was performed to compare the outcomes of MIS with OS. Seventeen outcomes were assessed.
Nine studies involving 382 patients were included. MIS was comparable in blood transfusion rate, R0 resection rate, lymph nodes received, overall morbidity, severe morbidity (Clavien-Dindo classification > = 3), bile leakage rate, wound infection rate, intra-abdominal infection rate, days until oral feeding, 1-year overall survival, 2-year overall survival and postoperative mortality with OS. Although operation time was longer (mean difference (MD) = 93.51, 95% confidence interval (CI) = 64.10 to 122.91, P < 0.00001) and hospital cost (MD = 0.68, 95% CI = 0.03 to 1.33, P = 0.04) was higher in MIS, MIS was associated with advantages of minimal invasiveness, that was less blood loss (MD = -81.85, 95% CI = -92.09 to -71.62, P < 0.00001), less postoperative pain (MD = -1.21, 95% CI = -1.63 to -0.79, P < 0.00001), and shorter hospital stay (MD = -4.22, 95% CI = -5.65 to -2.80, P < 0.00001).
The safety and feasibility of MIS for HCCA is acceptable in selected patients. MIS is a remarkable alternative to OS for providing comparable outcomes associated with a benefit of minimal invasiveness and its application should be considered more.
微创外科(MIS)为肝门部胆管癌(HCCA)患者提供了一种新的治疗方法。然而,它是否能达到与传统开腹手术(OS)相同的效果仍存在争议。
为了评估 MIS 治疗 HCCA 的安全性和可行性,我们进行了一项系统评价和荟萃分析,比较了 MIS 与 OS 的治疗效果。评估了 17 项结果。
纳入了 9 项研究共 382 例患者。MIS 在输血率、R0 切除率、淋巴结清扫数、总并发症发生率、严重并发症发生率(Clavien-Dindo 分级≥3)、胆漏发生率、切口感染率、腹腔感染率、开始口服饮食时间、1 年总生存率、2 年总生存率和术后死亡率方面与 OS 相当。尽管 MIS 的手术时间较长(均数差(MD)=93.51,95%置信区间(CI)=64.10 至 122.91,P<0.00001),且住院费用较高(MD=0.68,95%CI=0.03 至 1.33,P=0.04),但 MIS 具有微创优势,术中出血量更少(MD=-81.85,95%CI=-92.09 至-71.62,P<0.00001),术后疼痛较轻(MD=-1.21,95%CI=-1.63 至-0.79,P<0.00001),住院时间较短(MD=-4.22,95%CI=-5.65 至-2.80,P<0.00001)。
在选择合适的患者中,MIS 治疗 HCCA 的安全性和可行性是可以接受的。MIS 是 OS 的一种显著替代方法,可提供相似的结果,并具有微创优势,应更多地考虑应用。